Article Sidebar

Submitted
13 March 2020
Published
1 June 2021
Download
PDF
Statistic
Read Counter : 605 Download : 794

Main Article Content

Abstract

According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Colon Cancer Version 2.2019, mCRC patients with mutant type RAS were treated with anti-VEGF. However, the use of the targeting therapy still had inconsistent results. Neoangiogenesis studies had been used as a basis to assess the prognosis of mCRC. Microvascular density (MVD) had become the morphological gold standard to assess neovascularization in human tumors. This study proved the existence of low microvascular density (MVD) in mCRC patients with mutant type RAS status as a predictor of failure of anti-VEGF therapy. There were 29 patients at Dr. Soetomo Academic Hospital from 2015-2018 who had their RAS status checked and tested for microvascular density (MVD). The results of this study were analyzed using SPSS 23.0. In the Mutant-type of RAS group, this study examined microvascular density (MVD). 11 (73%) research subjects with high MVD scores and 4 (27%) research subjects had low MVD scores. Besides, 27% microvascular density (MVD) was low, in the mutant-type of RAS mCRC patient which could be a predictor factor for the failure of anti-VEGF therapy.

Keywords

Metastatic Colorectal Cancer Microvascular Density RAS tipe Mutan Bevacizumab

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Sulistyo, H., & Budipramana, V. S. (2021). Examination of Micro Vascular Density on Metastatic Colorectal Cancer of RAS Mutant-Type as Anti Vegf Therapy Predictor. Folia Medica Indonesiana, 57(2), 111–116. https://doi.org/10.20473/fmi.v57i2.18249
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Anannamcharoen S, Nimmanon T (2012). Study of the vascular endothelial growth factor (VEGF) expression and microvascular density (MVD) in primary colorectal cancer specimens. J Med Assoc Thai 95, 1041-7.
  2. Baraniskin A, Buchberger B, Pox C, et al (2019). Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Eur. J. Cancer 106, 37–44.
  3. Cercek A, Braghiroli MI, Chou JF, et al (2017). Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations. Clin Cancer Res 23, 4753-4760.
  4. Chen D, Gu K, Wang H (2019). Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: Current results and controversies. Cancer Manag Res 11, 1705-1716.
  5. Chabowski M, Nowak A, Grzegrzolka J, et al (2018). Comparison of microvessel density using nestin and CD34 in colorectal cancer. Anticancer Research 38, 3889-3895.
  6. El Sabaa BM, Meleiss M, Zaki I (2012). VEGF expression and microvascular density in relation to high-risk-HPV infection in cervical carcinoma – An immunohistochemical study. Alexandria Journal of Medicine 48, 47-57.
  7. Grivas N, Goussia A, Stefanou D, et al (2016). Microvascular density and immune histochemical expression of VEGF, VEGFR-1 and VEGFR-2 in benign prostatic hyperplasia, high-grade prostate intraepithelial neoplasia and prostate cancer 69, 63-71.
  8. Kazazi-Hyseni F, Beijnen JH, Schellens JHM (2010). Bevacizumab. Oncologist 15, 819-825.
  9. Liang JT, Huang KC, Jeng YM, et al (2004). Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br J Surg 91, 355-361.
  10. NCCN Foundation (2019). Colon cancer, NCCN Foundation, Inc, United States, p 1-88.
  11. Rawla P, Sunkara T, Barsouk A (2019). Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 14, 89-103.
  12. Rumpold H, NiedersüíŸ-Beke D, Heiler C, et al (2020). Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. BMC Cancer 20, 1-9.
  13. Sugarbaker PH (2014). Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. World J Gastroenterol 20, 9286-9291.
  14. Sujindra E, Bupathy A (2016). Adolescents friendly health services: Perceptions and practice of medical professionals. International Journal of Reproduction, Contraception, Obstetrics and Gynecology 5, 2968-2972.
  15. Yu Y, Lee P, Ke Y, et al (2010). A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLOS ONE 5, 1-12.